Who we are
ABOUT MEDICINES FOR EUROPE
PURPOSE AND OBJECTIVES
OUR VALUES – OUR 5 PILLARS
STRUCTURE
MEMBERS
BECOME A MEMBER
CODE OF CONDUCT
DISCLOSURE
Vacancies
Manifesto 2024
Key topics
ACCESS
INDUSTRIAL POLICY
REGULATORY AND LEGAL FRAMEWORK
FALSIFIED MEDICINES
ENVIRONMENT
ANTIMICROBIAL RESISTANCE
MEDICINE SHORTAGES
COVID-19
Publications
EXTERNAL RESOURCES
FACTSHEETS
INFOGRAPHICS
PODCAST
POLICY
REPORTS
VIDEOS
Newsroom
IN THE NEWS
PRESS RELEASES
Contact us
Login
Generic medicines
Home
Medicines for Europe
Generic medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Biosimilar medicines
Home
Medicines for Europe
Biosimilar medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
DEFINITION
THERAPEUTIC AREAS
GLOSSARY
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
External resources
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Related links
Contact us
Twitter
Value added medicines
Home
Who we are
Value added medicines Group
MISSION AND VISION
STRUCTURE
MEMBERS
BECOME A MEMBER
Did you know?
Definition
THERAPEUTIC AREAS
Q&A
What’s new
FACTSHEETS
POLICY
REPORTS
VIDEOS
INFOGRAPHICS
Our 5 pillars
Patients
QUALITY
VALUE
SUSTAINABILITY
PARTNERSHIP
Find out more
Contact us
Events
Newsroom
Filters:
press-releases
x
2020
x
News about
By type
In the news
Press releases
Twitter
Tweets
Videos
Photos
All routes to healthcare efficiency include biosimilar medicines
9 December 2020
Read More
EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines
25 November 2020
Read More
IGBA Launches First Global Biosimilars Week
16 November 2020
Read More
European Health Union – first step to greater EU solidarity in health crisis situations
11 November 2020
Read More
Joint EU-UK pharmaceutical industry response to Specialised Committee outcome
9 November 2020
READ MORE
Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines
5 November 2020
Read More
Open letter from Medicines for Europe Executive on the upcoming EU pharmaceutical strategy
20 October 2020
Read More
Statement from the President: Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing
7 October 2020
Berlin, 07 October 2020, speaking at ‘For a Healthy Europe’, […]
Read more
IGBA: Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics
24 September 2020
READ MORE
Joint press statement of European Pharmaceutical industry associations
17 September 2020
READ MORE
Posts navigation
1
2
3
…
5
Subscribe to our newsletter
[contact-form-7 id="1638" title="Newsletter subscription"]
Medicines For Europe
Who we are
Vacancies
Manifesto 2024
Key topics
Publications
Newsroom
Contact us
SECTOR GROUPS
Generic medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Biosimilar medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
FIND OUT MORE
Value added medicines
WHO WE ARE
DID YOU KNOW?
WHAT’S NEW
OUR 5 PILLARS
Events
Share This
LinkedIn
Share on Mastodon
Enter your Mastodon instance URL (optional)
Share
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Ok